Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.62 |
| ▸ | MAPK13 | O15264 | 15/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 15/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 15/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.52 |
| ▸ | RAF1 | P04049 | 3/20 | 0.49 |
| ▸ | IDH1 | O75874 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785137 | 0.87 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7560872 | 0.86 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7560881 | 0.86 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6172307 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6171760 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6171469 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6171754 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL6171462 | 0.86 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL7468591 | 0.85 | TRPC3 (0.42) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL7670671 | 0.84 | TRPC3 (0.43) | MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6350744-B1 | PYRMIDINE OR PYRIDINE DERIVATIVES; ANTIARTHRITIC AND ANTIINFLAMMATORY AGENTS; CACHEXIA TREATMENT; INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |